Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01767701 (ClinicalTrials.gov)	April 2013	7/1/2013	Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis	A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI	Relapsing Remitting Multiple Sclerosis	Drug: Raltegravir	Queen Mary University of London	Merck Sharp & Dohme Corp.	Completed	18 Years	55 Years	All	23	Phase 2	United Kingdom
2	EUCTR2012-004847-61-GB (EUCTR)	16/01/2013	18/12/2012	INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS	A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI - INSPIRE (Isentress Pilot Study in Relapsing MS)	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: ISENTRESS Product Name: raltegravir INN or Proposed INN: lactose monohydrate	Queen Mary University of London	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 2	United Kingdom